Spotlight On... Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer; Bristol-Myers' Daklinza wins access to bigger hep C market; Cigna inks outcomes-linked deal on Novartis' Entresto; and more...

Pfizer's ($PFE) Ibrance has already been prescribed to more than 20,000 patients, and the company says it has a "very heavy" clinical trial program testing it in multiple types of breast cancer and beyond. But Pfizer may need that head start and more to stay ahead of a pair of up-and-comers currently in its rivals' pipelines. More from FiercePharmaMarketing

@FiercePharma: Report: Veterinary prices rise modestly as clinics charge more for routine services. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: FDA shoots down Vertex's latest bid for Kalydeco expansion. Article | Follow @CarlyHFierce

> The FDA green-lighted Bristol-Myers Squibb's ($BMY) Daklinza for more hard-to-treat hep C patients. Release

> Cigna announced that it has entered into an outcomes-based contract with Novartis ($NVS) over heart-failure newcomer Entresto. More

> Top FDA official Janet Woodcock told a congressional committee that she's expecting a deluge of biosimilars applications and may need more resources to handle them. Report

> The U.S. Justice Department is investigating possible fraud among compounding pharmacies that hawk pricey pain-relief creams. Report

Medical Device News

@FierceMedDev: ICYMI: Nikon makes strategic investment in Thiel-backed cheap, safe handheld X-ray startup. Article | Follow @FierceMedDev

@EmilyWFierce: PhRMA is planning on spending millions this year to clean up the drug industry's tarnished rep. More from the WSJ (sub. req.) | Follow @EmilyWFierce

> U.K. engineering company Halma purchases maker of real-time hospital monitors for $140M. Story

> Former BD CEO backs Velano Vascular in $3.5M for needle-free blood draw device. Article

Biotech News

@FierceBiotech: Baxalta partner CTI plunges after FDA slaps partial hold on PhIII myelofibrosis drug. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: UPDATED: A patient in Akashi's suspended Duchenne MD trial dies. More | Follow @JohnCFierce

> Biogen joins a GSK-led data-sharing project to make R&D more efficient. Report

> Sarepta faces another FDA delay with its much-scrutinized DMD drug. Story

> AstraZeneca's cancer checkpoint combo looks promising in small lung cancer study. Article

Animal Health News

> Scientists pinpoint contributions pets can make to human medicine. Report

> Currency woes overshadow Merck's 2015 growth in animal health. Item

> UPenn veterinary students to star in new Animal Planet reality show. Story

> Report: Veterinary prices rise modestly as clinics charge more for routine services. More

> Stem cell therapy developed to treat dental disease in cats could also help people. Article

Biotech IT News

> 454 Life Sciences, Ion Torrent founder raises $40M for tech-enabled drug development shop. Report

> In silico discovery platform drives forward Bavarian Nordic's MRSA vaccine program. More

> Buzz: Roche weighing up bid for Pacific Biosciences. Item

> U.K. looks to house software developers at planned cancer research hub. Story

> Illumina signs biobank deals to fuse genome data, EMRs. Article

Pharma Marketing News

> Docs take aim at Novartis' 'horrifying' Entresto ad. Article

> Valeant, AstraZeneca played the Super Bowl ad game, but did they win? Item

> GSK's slow-off-the-blocks Anoro gets a leg up from Incruse sidekick. Story

> Omega diet-aid ad banned in U.K.; summer slimming promos not 'socially responsible.' Article

> 'Safe' social network LinkedIn emerges as popular marketing tool for pharma. Report

And Finally... Merck & Co.'s ($MRK) recent Vioxx-related settlement in New Jersey is expected to trigger a $150 million hit to the directors' and officers' insurance market. Report

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.